<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910417-0105</DOCNO><DOCID>910417-0105.</DOCID><HL>   Who's News:   Cell Technology Adds   Three to Board Seats</HL><DATE>04/17/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   CELL DOW WNEWS</CO><MS>BASIC MATERIALS (BSC)TECHNOLOGY (TEC)</MS><IN>CHEMICALS, PLASTICS (CHM)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>PERSONNEL ANNOUNCEMENTS, PROMOTIONS, APPOINTMENTS (PER)ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>COLORADO (CO)MICHIGAN (MI)</RE><LP>   BOULDER, Colo. -- Cell Technology Inc. said it increasedthe size of its board to seven members from four and namedthree additional directors to serve immediately.   The new directors are Richard D. Johnson, formerly a vicepresident of Marion Merrell Dow; Samuel H. Gray, chiefexecutive officer of Kalipharma Inc.; and Alf Bjorseth, asenior vice president of Elkem AS of Norway.</LP><TEXT>   The selection of the three board members follows thecompany's plans to acquire Pioneer Pharmaceuticals, a NewJersey unit of Dow Chemical Co. of Midland, Mich.   Separately, the company said it adjusted the exerciseprice and redemption terms of its 1987 warrants to purchasecommon stock to comply with antidilutive provisions governingthem.   To compensate for stock and options issued to companyconsultants and directors, Cell said it had reduced theper-share exercise price from $5.73 to $5.57 and increasedthe amount of common stock issuable for each warrant from1.395 shares to 1.435.   The company said it also lowered the trading price thattriggers its right to redeem the warrants from an average of$7.17 for 20 consecutive trading days to $6.97. Theredemption price remains seven cents per warrant.   In national over-the-counter trading, Cell shares werequoted at $1.90625, up 9.375 cents.   ---   Corrections andamp; Amplifications   SAMUEL H. GRAY, a director of Cell Technology Inc.,formerly was chief executive officer of Kalipharma Inc.Wednesday's edition misstated Mr. Gray's relationship withKalipharma.   (WSJ April 22, 1991)</TEXT></DOC>